154 related articles for article (PubMed ID: 25152611)
1. Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%.
Bergmann MT; Williams JI; Gomes PJ
Clin Ophthalmol; 2014; 8():1495-505. PubMed ID: 25152611
[TBL] [Abstract][Full Text] [Related]
2. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
3. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
[TBL] [Abstract][Full Text] [Related]
4. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
Macejko TT; Bergmann MT; Williams JI; Gow JA; Gomes PJ; McNamara TR; Abelson MB;
Am J Ophthalmol; 2010 Jul; 150(1):122-127.e5. PubMed ID: 20488431
[TBL] [Abstract][Full Text] [Related]
5. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.
Meier EJ; Torkildsen GL; Gow JA; McNamara TR; Gomes PJ; Williams JI;
Allergy Asthma Proc; 2012; 33(3):265-74. PubMed ID: 22991696
[TBL] [Abstract][Full Text] [Related]
6. Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis.
Cavet ME; Gomes PJ; Carr WW; Williams JI
J Asthma Allergy; 2018; 11():29-39. PubMed ID: 29615844
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM
Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
Crampton HJ
Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.
Torkildsen GL; Abelson MB; Gomes PJ
Clin Ther; 2008 Jul; 30(7):1272-82. PubMed ID: 18691986
[TBL] [Abstract][Full Text] [Related]
10. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model.
Ackerman S; D'Ambrosio F; Greiner JV; Villanueva L; Ciolino JB; Hollander DA
J Asthma Allergy; 2013; 6():43-52. PubMed ID: 24109191
[TBL] [Abstract][Full Text] [Related]
11. Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model.
Meier EJ; Torkildsen GL; Gomes PJ; Jasek MC
Clin Ophthalmol; 2018; 12():2617-2628. PubMed ID: 30587908
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
Spangler DL; Abelson MB; Ober A; Gotnes PJ
Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
14. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.
Torkildsen GL; Williams JI; Gow JA; Gomes PJ; Abelson MB; McNamara TR;
Ann Allergy Asthma Immunol; 2010 Jul; 105(1):57-64. PubMed ID: 20642205
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial.
Carr WW; Nayak AS; Ratner PH; Gow JA; McNamara TR; Williams JI;
Allergy Asthma Proc; 2013; 34(3):247-54. PubMed ID: 23484763
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Spangler DL; Bensch G; Berdy GJ
Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model.
Abelson MB; Kaplan AP
Clin Ther; 2002 Mar; 24(3):445-56. PubMed ID: 11952027
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.
D'Arienzo PA; Leonardi A; Bensch G
Clin Ther; 2002 Mar; 24(3):409-16. PubMed ID: 11952024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
